The Effect of Oral Nicotinamide Riboside on Systemic Vascular Perfusion in Heathy Adults

Overview

About this study

The purpose of this study is to better understand the effects of oral nicotinamide riboside (NR) on systemic vascular perfusion in a cohort of healthy adults.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Healthy adult males and females.
  • Between the ages of 40 and 60.
  • Provides consent to participate in the study.
  • Understands and agrees to follow all study procedures and limitations.

Exclusion Criteria:

  • Pregnant, nursing, or trying to conceive.
  • BMI restrictions: < 30.
  • Allergy or sensitivity to study agent ingredients.
  • Hypertension treated with medication.
  • Use of natural health products containing nicotinamide riboside, quercetin, trans-resveratrol, or betaine anhydrous within 7 days prior to randomization and during the course of the study. 
  • Surgery planned during the course of the trial.
  • History or past diagnosis of chronic diseases, unstable medical conditions, blood/bleeding disorders or stroke.
  • History or current diagnosis of cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening or cancer in full remission more than 5 years after diagnosis.
  • Abnormal blood chemistries for renal or liver function (defined as 1 standard deviation outside of the normal range), alcohol dependence, uncontrolled thyroid disease, severe obesity (body mass index > 40 kg m^2), or weight stable for at least 3 months prior to enrolling in the study (defined as > 2 kg change in body mass).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/25/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ryan Hurt, M.D., Ph.D.

Open for enrollment

Contact information:

Snigdha Panda

(507) 538-5827

GIMRESEARCHSTUDIES@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20566391

Mayo Clinic Footer